e-ISSN: 2747-2051

Archives of the Medicine and Case Reports

[AMCR]

https://hmpublisher.com/index.php/amcr

Impact of mRNA COVID-19 Vaccines on Blood Pressure in Hypertensive Patients: A Retrospective Observational Study

Mugi Rahma Raysyifa[1*], Khamdiyah Indah Kurniasih[1], Siti Setianingsih[1]

[1]Bachelor of Pharmacy Study Program, Universitas Harapan Bangsa, Purwokerto, Indonesia

ARTICLE INFO

Keywords:
Blood pressure
Cardiovascular risk
COVID-19
Hypertension
mRNA vaccines

***Corresponding author:**
Mugi Rahma Raysyifa

E-mail address:
rahmaraysyifaa@gmail.com

All authors have reviewed and approved the final version of the manuscript.

https://doi.org/10.37275/amcr.v5i4.628

ABSTRACT

The COVID-19 pandemic necessitated rapid vaccine development, with mRNA vaccines (Moderna or Pfizer) emerging as frontrunners. While effective, concerns arose regarding their impact on blood pressure (BP), particularly in hypertensive individuals, a population already at increased cardiovascular risk. The study aimed to investigate the effects of mRNA COVID-19 vaccines on BP in hypertensive patients. A retrospective observational study was conducted at the Mrebet Community Health Center. Data from hypertensive patients receiving the second dose of either Moderna or Pfizer vaccine were analyzed. Pre- and post-vaccination BP readings, patient demographics, medication profiles, and hypertension severity were assessed. Statistical analysis was performed to evaluate changes in BP and identify potential associations. The study included 33 hypertensive patients (mean age: 55.2 years, 84.8% female). The majority (84.8%) received the Moderna vaccine. Pre- and post-vaccination BP readings showed a slight increase in systolic BP (133 mmHg to 137 mmHg) and a minor decrease in diastolic BP (85 mmHg to 84 mmHg). Statistical analysis revealed a significant association between vaccination and changes in diastolic BP ($p < 0.05$), but not systolic BP ($p > 0.05$). In conclusion, mRNA COVID-19 vaccines may have a modest impact on BP in hypertensive patients, particularly on diastolic BP. The clinical significance of these changes warrants further investigation. Close monitoring of BP in hypertensive individuals post-vaccination is recommended.

1. Introduction

The emergence of the novel coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), in late 2019 precipitated an unprecedented global health crisis, the COVID-19 pandemic. The rapid spread of the virus and its associated morbidity and mortality underscored the urgent need for effective preventive measures. The development and deployment of vaccines, particularly the groundbreaking mRNA vaccines (Pfizer-BioNTech and Moderna), represented a pivotal turning point in the fight against the pandemic. These mRNA vaccines, based on innovative technology that delivers genetic instructions to cells to produce viral proteins, demonstrated remarkable efficacy in clinical trials and real-world settings. They proved highly effective in preventing severe illness, hospitalization, and death associated with COVID-19, offering a glimmer of hope in the face of a devastating pandemic. The vaccines' success stemmed from their ability to elicit robust immune responses, including the production of neutralizing antibodies and T cells that target the virus's spike protein, thereby preventing infection and mitigating disease severity.[1-3]

However, amidst the widespread acclaim for mRNA vaccines, concerns arose regarding their potential impact on blood pressure (BP), particularly in individuals with pre-existing hypertension.

Hypertension, a chronic condition characterized by elevated BP, is a major risk factor for cardiovascular diseases, including heart attack, stroke, and heart failure. The potential for vaccines to influence BP, even transiently, raised concerns about the safety and tolerability of these vaccines in hypertensive individuals, a population already at increased cardiovascular risk. The interplay between COVID-19 and hypertension is complex and multifaceted. Hypertension has been identified as a significant risk factor for severe COVID-19 illness and mortality. The underlying mechanisms are thought to involve the renin-angiotensin system (RAS), a hormonal system that regulates BP and fluid balance. The SARS-CoV-2 virus utilizes the ACE2 receptor, a key component of the RAS, to gain entry into cells. This interaction can disrupt the RAS balance, potentially contributing to BP dysregulation and exacerbating cardiovascular complications in hypertensive individuals.[4,5]

Furthermore, the inflammatory response triggered by COVID-19 infection can further elevate BP and increase the risk of cardiovascular events. The virus can induce endothelial dysfunction, impairing the ability of blood vessels to dilate and constrict appropriately. This dysfunction, coupled with the activation of the sympathetic nervous system and the release of inflammatory mediators, can lead to a cascade of events that culminate in elevated BP and increased cardiovascular stress. Given the intricate relationship between COVID-19 and hypertension, it is imperative to understand the potential impact of mRNA vaccines on BP in this vulnerable population. Several studies and case reports have documented instances of BP fluctuations following mRNA COVID-19 vaccination. Some individuals experienced increases in BP, while others reported decreases. The vaccine-induced immune response, while crucial for protection against COVID-19, can also trigger inflammation and the release of cytokines, which can influence BP. As mentioned earlier, the SARS-CoV-2 spike protein can interact with the ACE2 receptor, potentially disrupting the RAS and contributing to BP changes. Individuals with pre-existing cardiovascular conditions, such as hypertension, may be more susceptible to BP fluctuations after vaccination due to their underlying vascular dysfunction and heightened sensitivity to inflammatory stimuli. The vaccination process itself can induce stress and anxiety, which can transiently elevate BP.[6,7]

The clinical significance of these BP changes is a subject of ongoing debate. While some studies suggest that the fluctuations are generally mild and self-limiting, others raise concerns about potential long-term consequences, especially in individuals with poorly controlled hypertension. Understanding the impact of mRNA COVID-19 vaccines on BP in hypertensive patients is crucial for optimizing vaccine safety and minimizing cardiovascular risks.[8-10] This retrospective observational study aimed to investigate the effects of mRNA COVID-19 vaccines on BP in hypertensive patients at the Mrebet Community Health Center. By analyzing pre- and post-vaccination BP readings, along with patient demographics, medication profiles, and hypertension severity, we sought to shed light on the potential relationship between mRNA vaccination and BP changes in this population. The study's findings contribute to the growing body of knowledge on the safety and tolerability of mRNA vaccines in hypertensive individuals, informing clinical practice and public health recommendations.

2. Methods

The study adopted a retrospective observational design, which involves the examination of pre-existing data to identify potential associations and trends. This approach is particularly suitable for investigating the effects of interventions, such as vaccination, in real-world settings. The retrospective nature of the study allowed for the efficient utilization of existing data, minimizing the need for prospective data collection and reducing the burden on patients and healthcare providers. The study was conducted at the Mrebet Community Health Center, a primary healthcare facility serving a diverse population in the region. The health center maintains comprehensive electronic medical records (EMRs) for its patients, providing a valuable source of data for retrospective research. The choice of this setting ensured access to a representative sample of hypertensive patients who had received mRNA COVID-19 vaccines, facilitating the investigation of the research question in a real-world context.

The study population consisted of hypertensive patients enrolled in the Prolanis (*Program Pengendalian Penyakit Kronis*) program at the Mrebet Community Health Center. Prolanis is a nationwide initiative aimed at improving the quality of life for individuals with chronic diseases, including hypertension, through comprehensive disease management and health promotion strategies. The program provides regular health checkups, medication management, lifestyle counseling, and patient education, contributing to better control of chronic conditions and reducing the risk of complications. The inclusion criteria for the study were carefully defined to ensure the selection of an appropriate and representative sample of hypertensive patients who had received mRNA COVID-19 vaccines. The criteria included; Age: Patients aged 18 years or older were eligible for inclusion, ensuring that the study population encompassed adults across a wide age range; Hypertension diagnosis: A documented diagnosis of hypertension, based on clinical assessment and BP readings, was required for inclusion. This ensured that the study focused specifically on individuals with pre-existing hypertension, the target population of interest; mRNA vaccination: Receipt of the second dose of either the Moderna or Pfizer-BioNTech mRNA COVID-19 vaccine was mandatory for inclusion. This criterion ensured that the study examined the effects of complete vaccination with mRNA vaccines, which have been shown to elicit robust immune responses and provide significant protection against COVID-19; BP readings: The availability of both pre- and post-vaccination BP readings was essential for inclusion. Pre-vaccination BP was defined as measurements taken within one month before vaccination, while post-vaccination BP referred to measurements taken one month to one year after vaccination. This timeframe allowed for the assessment of both short-term and potential long-term effects of vaccination on BP. In addition to the inclusion criteria, exclusion criteria were also established to minimize the potential for confounding factors and ensure the validity of the study results. The exclusion criteria included; Significant comorbidities: Patients with a history of other significant comorbidities, such as diabetes, heart failure, or chronic kidney disease, were excluded. These conditions can independently influence BP and potentially confound the assessment of the vaccine's impact; Pregnancy or lactation: Pregnant or lactating women were excluded due to the potential risks associated with vaccination during these periods and the physiological changes in BP that occur during pregnancy; Incomplete or missing data: Patients with incomplete or missing data, particularly regarding BP readings or medication profiles, were excluded to maintain data integrity and ensure the reliability of the analysis.

The data collection process involved the systematic extraction of relevant information from the patients' EMRs. The EMRs at the Mrebet Community Health Center are maintained electronically, providing a secure and accessible repository of patient data. Trained research personnel, under the supervision of experienced clinicians, meticulously reviewed the EMRs of eligible patients and extracted the following data; Demographic data: This included basic demographic information such as age and sex, which can influence BP and potentially interact with the vaccine's effects; Vaccination details: The type of mRNA vaccine received (Moderna or Pfizer-BioNTech) and the date of the second dose were recorded. This information allowed for the comparison of potential differences in BP responses between the two vaccines; BP readings: Pre- and post-vaccination BP readings were carefully documented. Pre-vaccination BP was defined as the average of BP measurements taken within one month before vaccination, while post-vaccination BP was the average of measurements taken one month to one year after vaccination. This approach accounted for potential BP variability and ensured a comprehensive assessment of BP changes over time; Medication profile: The specific antihypertensive medications used by each patient, including dosage and frequency, were recorded. This information allowed for the evaluation of potential interactions between the vaccine and antihypertensive medications, which could influence BP responses; Hypertension severity: The severity of hypertension was classified according to the American Heart Association guidelines, which categorize BP into normal, elevated, stage 1 hypertension, and stage 2 hypertension based on systolic and diastolic BP readings. This classification provided a standardized assessment of hypertension severity and allowed for the investigation of potential differences in BP responses based on baseline BP levels.

The collected data were subjected to rigorous statistical analysis to identify potential associations and trends. Descriptive statistics, including means, standard deviations, and frequencies, were used to summarize patient characteristics and BP readings. Paired t-tests, a statistical method for comparing two related samples, were employed to assess the differences between pre- and post-vaccination BP values. This analysis allowed for the determination of whether any observed changes in BP were statistically significant. Pearson correlation coefficients, a measure of the linear relationship between two variables, were calculated to assess the association between pre- and post-vaccination BP readings. This analysis helped to identify any potential correlations between baseline BP and the magnitude of BP changes after vaccination. All statistical analyses were performed using SPSS version 26, a widely used statistical software package. The significance level was set at $p < 0.05$, indicating that a result was considered statistically significant if the probability of it occurring by chance was less than 5%.

3. Results and Discussion

Table 1 provides a snapshot of the key characteristics of the patient population involved in the study. The study included a total of 33 patients with hypertension. The mean age of the participants was 55.2 years, suggesting that the study primarily focused on middle-aged to older adults. The majority of the patients were female (84.8%), which is noteworthy as hypertension prevalence and management can differ between sexes. The age range of the participants was quite broad, spanning from 26 to 78 years. However, most patients (87.9%) fell within the age bracket of 46-65 years. This concentration in the middle-aged to early elderly population aligns with the typical demographic of individuals with hypertension, as the risk of developing this condition increases with age. The majority of the patients (84.8%) received the Moderna vaccine, while a smaller proportion (15.2%) received the Pfizer vaccine. This distribution reflects the availability and allocation of vaccines at the study site during the study period. The difference in vaccine types allows for a potential comparison of their impact on blood pressure, although the sample size for the Pfizer group is relatively small.

Table 1. Patient characteristics.

Characteristic	Value
Total patients	33
Mean age (years)	55.2
Age range (years)	26-78
Female (%)	84.80%
Age 46-65 years (%)	87.90%
Moderna vaccine (%)	84.80%
Pfizer vaccine (%)	15.20%

Table 2 provides insights into the antihypertensive medication regimens of the study participants. The most frequently prescribed medication was amlodipine, a calcium channel blocker (CCB). It was used as monotherapy in 42.4% of patients (10mg dose) and in combination with lisinopril in 24.2% of patients (10mg dose combined with 5mg lisinopril). This suggests that amlodipine is a favored first-line agent for managing hypertension in this population, likely due to its effectiveness, tolerability, and availability. A significant proportion of patients (24.2%) received a combination of amlodipine 10mg and lisinopril 5mg. This indicates that for some patients, monotherapy was insufficient to achieve adequate blood pressure control, necessitating the addition of a second agent. The combination of a CCB and an ACE inhibitor (lisinopril) targets different mechanisms of blood pressure regulation, potentially offering synergistic effects. While amlodipine was the most common medication, other antihypertensive agents were also used, albeit less frequently. Amlodipine 5mg was prescribed as monotherapy in 18.2% of patients, and lisinopril was used in varying doses (5mg and 10mg) as monotherapy or in combination with amlodipine in a small number of patients. The use of these medications highlights the individualized nature of hypertension management, as treatment choices are often tailored to the specific needs and characteristics of each patient. The text mentions that there were no changes in medication type or dosage before and after vaccination. This suggests that the observed blood pressure changes were not attributed to alterations in antihypertensive therapy but were likely related to the vaccination itself or other factors.

Table 2. Medication profile.

Medication regimen	Number of patients	Percentage (%)
Amlodipine 5mg	6	18.2
Amlodipine 10mg	14	42.4
Lisinopril 5mg	1	3
Lisinopril 10mg	3	9.1
Amlodipine 5mg + Lisinopril 5mg	1	3
Amlodipine 10mg + Lisinopril 5mg	8	24.2

Table 3 provides the changes in blood pressure (BP) before and after vaccination, along with their statistical significance. The average systolic BP increased slightly from 133 mmHg before vaccination to 137 mmHg after vaccination. However, this change was not statistically significant (p = 0.305), suggesting that it might have occurred by chance. The average diastolic BP decreased slightly from 85 mmHg to 84 mmHg. This change, although seemingly small, was statistically significant ($p < 0.001$), indicating a true effect of the vaccination on diastolic BP. While the changes in BP were statistically significant for diastolic BP, their clinical significance needs to be interpreted cautiously. A 4 mmHg increase in systolic BP and a 1 mmHg decrease in diastolic BP might not translate into meaningful clinical consequences for most patients. However, it underscores the importance of monitoring BP in hypertensive patients after vaccination, especially in those with borderline or poorly controlled BP. The observed changes in BP could be attributed to various factors, including the vaccine-induced immune response, interaction with the renin-angiotensin system, or pre-existing cardiovascular comorbidities. Further research is needed to elucidate the exact mechanisms underlying these changes.

Table 3. Blood pressure changes.

Blood pressure	Pre-vaccination (mmHg)	Post-vaccination (mmHg)	Change (mmHg)	p-value
Systolic	133	137	+4	0.305
Diastolic	85	84	-1	<0.001

Table 4 presents the distribution of hypertension severity categories among the patients before and after receiving the mRNA COVID-19 vaccine. The table shows a noticeable shift in the distribution of hypertension severity categories after vaccination. The number of patients in the pre-hypertension category decreased from 27 to 21, while the number of patients in stage 1 hypertension increased from 6 to 12. This suggests that vaccination might be associated with a progression to a higher severity category in some patients.

Table 4. Hypertension severity.

Hypertension severity	Pre-vaccination	Post-vaccination
Pre-hypertension	27	21
Stage 1 hypertension	6	12

The findings of this study, which indicate a slight increase in systolic blood pressure (SBP) and a small decrease in diastolic blood pressure (DBP) following mRNA COVID-19 vaccination in hypertensive patients, offer valuable insights into the potential impact of these vaccines on blood pressure regulation. The observed changes, while seemingly minor, warrant careful consideration due to the potential long-term implications for cardiovascular health, particularly in individuals already predisposed to hypertension. The study noted a slight increase in SBP from a mean of 133 mmHg pre-vaccination to 137 mmHg post-vaccination. Although this 4 mmHg rise did not achieve statistical significance (p = 0.305), it cannot be dismissed entirely. The lack of statistical significance could be attributed to the relatively small sample size of the study (33 patients), which might have limited the power to detect subtle changes. Moreover, the observational nature of the study, without a control group, makes it challenging to definitively attribute the SBP increase solely to the vaccination, as other factors such as lifestyle changes or underlying disease progression could also have played a role. Nevertheless, even a modest increase in SBP can have clinical ramifications, especially in hypertensive individuals. The long-term effects of sustained, even slightly elevated, SBP can include increased arterial stiffness, left ventricular hypertrophy, and accelerated atherosclerosis, all of which contribute to an elevated risk of cardiovascular events such as heart attack and stroke. Therefore, it is crucial to monitor SBP closely in hypertensive patients following mRNA COVID-19 vaccination, even if the initial increase appears minor. The study's finding of a slight decrease in DBP from 85 mmHg to 84 mmHg, although statistically significant ($p < 0.001$), presents an interesting contrast to some previous studies that reported increases in both SBP and DBP after mRNA vaccination. This discrepancy could be attributed to several factors, including differences in study populations, vaccination protocols, or measurement techniques. For instance, the study population in this research consisted primarily of middle-aged to older females, a demographic that might exhibit different BP responses compared to other groups. Additionally, the specific timing and frequency of BP measurements could influence the observed changes. The decrease in DBP, while seemingly beneficial, also warrants careful interpretation. DBP represents the pressure in the arteries when the heart is at rest between beats. A decrease in DBP could indicate improved vascular relaxation or decreased peripheral resistance. However, it could also be a sign of reduced cardiac output or other underlying cardiovascular issues. Therefore, it is essential to consider the DBP decrease in conjunction with other clinical parameters and individual patient characteristics. The clinical significance of the observed BP changes remains a subject of ongoing investigation. While the changes in this study were relatively small, their long-term implications, particularly in the context of pre-existing hypertension, cannot be overlooked. Even minor BP fluctuations can contribute to cumulative cardiovascular risk over time. The progression to a higher hypertension severity category observed in some patients further underscores the potential impact of vaccination on BP regulation and the need for vigilance in monitoring and managing BP in this population. The mechanisms underlying the observed blood pressure (BP) changes after mRNA COVID-19 vaccination are likely complex and multifaceted, involving an interplay of various physiological and immunological factors. The following discussion elaborates on the potential mechanisms proposed in the context of the study's findings and the broader scientific literature. The administration of mRNA COVID-19 vaccines triggers a robust immune response, which is crucial for generating protective immunity against the virus. However, this immune response can also elicit a cascade of inflammatory events, characterized by the release of cytokines and other inflammatory mediators. These molecules can exert diverse effects on the cardiovascular system, including influencing vascular tone and reactivity, which can ultimately lead to fluctuations in BP. The temporal association between vaccination and BP changes observed in this study and others lends credence to the hypothesis that the immune response plays a pivotal role in these fluctuations. The increase in systolic BP, although not statistically significant in this study, could be attributed to the vasoconstrictive effects of certain cytokines, such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α). These cytokines have been implicated in the development of hypertension and can induce oxidative stress, endothelial dysfunction, and vascular remodeling, leading to increased peripheral vascular resistance and elevated BP. The decrease in diastolic BP, on the other hand, might be related to the vasodilatory effects of other inflammatory mediators or a compensatory response to the slight increase in systolic BP. The complex interplay between various cytokines and vasoactive substances released during the immune response could result in a net effect on BP that varies depending on individual factors and the specific vaccine administered. Furthermore, the activation of immune cells, such as macrophages and T cells, during the immune response can also contribute to BP changes. These cells can release various vasoactive substances, including nitric oxide, endothelin-1, and reactive oxygen species, which can modulate vascular tone and BP. The balance between vasoconstrictive and vasodilatory factors released by immune cells could influence the overall BP response to vaccination. The renin-angiotensin system (RAS) is a critical hormonal system that regulates BP and fluid balance. The SARS-CoV-2 spike protein, which is the target of mRNA vaccines, binds to the angiotensin-converting enzyme 2 (ACE2) receptor on cell surfaces. ACE2 is a key component of the RAS, and its interaction with the spike protein can lead to internalization and degradation of the receptor. This disruption of ACE2 function can potentially disturb the delicate balance of the RAS, contributing to BP elevation. The downregulation of ACE2 can lead to an accumulation of angiotensin II, a potent vasoconstrictor, and a decrease in angiotensin-(1-7), a vasodilator. This imbalance can result in increased vascular tone, heightened sympathetic nervous system activity, and sodium and water retention, all of which can contribute to elevated BP. The potential role of RAS dysregulation in the BP changes observed after mRNA vaccination is supported by studies demonstrating an association between ACE2 expression and BP levels. Furthermore, the inflammatory response triggered by vaccination can further exacerbate RAS dysfunction. Cytokines and other inflammatory mediators can stimulate the production of angiotensin II and inhibit the activity of ACE2, further promoting vasoconstriction and BP elevation. The interplay between the immune response and the RAS represents a complex and dynamic process that can significantly impact BP regulation. The endothelium, the inner lining of blood vessels, plays a crucial role in maintaining vascular homeostasis and regulating BP. It produces various vasoactive substances, including nitric oxide, endothelin-1, and prostacyclin, which modulate vascular tone and blood flow. COVID-19 infection and the associated inflammatory response can induce endothelial dysfunction, characterized by impaired production of vasodilators and increased production of vasoconstrictors. This dysfunction can contribute to BP elevation and increase the risk of cardiovascular complications. It is plausible that mRNA vaccines, through their immune-stimulating effects, could also transiently affect endothelial function and contribute to BP changes. The vaccine-induced immune response could lead to the release of reactive oxygen species and other inflammatory mediators that damage the endothelium and impair its production of nitric oxide, a potent vasodilator. This could result in vasoconstriction and increased BP, particularly in individuals with pre-existing endothelial dysfunction or hypertension. The vaccination process itself, particularly for individuals with needle phobia or anxiety about potential side effects, can induce stress and anxiety. These psychological factors can activate the sympathetic nervous system, the body's "fight-or-flight" response. Sympathetic activation leads to the release of catecholamines, such as adrenaline and noradrenaline, which can increase heart rate, cardiac output, and vascular tone, resulting in elevated BP. While the BP elevation associated with sympathetic activation is typically transient, it could contribute to the short-term BP fluctuations observed after vaccination. In individuals with pre-existing hypertension or other cardiovascular risk factors, even brief episodes of elevated BP could have detrimental consequences. Therefore, it is important to consider the potential role of stress and anxiety in BP responses to vaccination and implement strategies to mitigate their impact. Individuals with pre-existing cardiovascular conditions, such as hypertension, may be more susceptible to BP fluctuations after vaccination due to their underlying vascular dysfunction and heightened sensitivity to inflammatory stimuli. The presence of comorbidities could amplify the effects of the vaccine on BP regulation, potentially leading to more pronounced changes. In hypertensive individuals, the vascular endothelium may already be compromised, with impaired production of vasodilators and increased production of vasoconstrictors. The vaccine-induced immune response and inflammation could further exacerbate this endothelial dysfunction, leading to greater BP elevation. Additionally, individuals with comorbidities may have a less resilient cardiovascular system, making them more vulnerable to the BP effects of the vaccine-induced immune response and inflammation. While this study did not observe any changes in antihypertensive medication use before and after vaccination, potential interactions between the vaccine and certain medications cannot be entirely ruled out. Some medications, particularly those that affect the immune system or the RAS, could theoretically interact with the vaccine and influence BP responses. For example, medications that suppress the immune system, such as corticosteroids or immunosuppressants, could potentially dampen the vaccine-induced immune response and its associated BP effects. Conversely, medications that block the RAS, such as ACE inhibitors or angiotensin receptor blockers (ARBs), could interfere with the potential BP-elevating effects of ACE2 downregulation. Further research is needed to investigate the potential interactions between mRNA COVID-19 vaccines and various medications, particularly in individuals with pre-existing conditions such as hypertension. Understanding these interactions could help optimize medication management and minimize the risk of adverse BP effects after vaccination.[11,12]

The findings of the present study, while generally aligning with the broader landscape of research on the impact of mRNA COVID-19 vaccines on blood pressure (BP) in hypertensive patients, also present certain discrepancies that warrant further exploration. The following discussion delves into the comparison of the study's findings with previous reports, highlighting both consistencies and inconsistencies, and underscores the need for further research to clarify the precise effects of these vaccines on BP regulation. The observation of BP fluctuations following mRNA COVID-19 vaccination in this study resonates with several previous reports. The meta-analysis by Angeli et al. (2022), which synthesized data from multiple studies, revealed a small but statistically significant increase in both systolic and diastolic BP after vaccination, particularly following the second dose or booster shot. This suggests a potential, albeit subtle, impact of mRNA vaccines on BP regulation, which is further corroborated by the findings of the present study. Similarly, the study by Simonini et al. (2020) reported an 11% increase in BP among hypertensive patients on antihypertensive medications after mRNA vaccination. This observation aligns with the general trend of BP elevation reported in some studies, although the magnitude of the increase in the present study was less pronounced. The consistency between these findings and previous reports strengthens the evidence for a potential association between mRNA COVID-19 vaccines and BP changes in hypertensive individuals.[13,14]

The findings of this study carry significant clinical implications, particularly for the management of hypertensive patients receiving mRNA COVID-19 vaccines. The observed blood pressure (BP) changes, although subtle, underscore the need for heightened vigilance and proactive measures to ensure the cardiovascular well-being of this vulnerable population. The following discussion elaborates on the potential clinical implications of the study's findings, emphasizing the importance of BP monitoring, medication adjustment, patient education, and risk stratification. The study's observation of BP fluctuations, particularly the statistically significant decrease in diastolic BP, underscores the critical importance of close BP monitoring in hypertensive individuals following mRNA COVID-19 vaccination. The early detection of any significant BP changes can enable timely interventions, preventing potential complications and ensuring optimal cardiovascular health. The ideal frequency and timing of BP monitoring post-vaccination may vary depending on individual patient characteristics and risk factors. However, it is generally recommended that hypertensive patients monitor their BP more frequently in the days and weeks following vaccination. This could involve daily or even twice-daily measurements, especially for those with poorly controlled hypertension or other cardiovascular comorbidities. The frequency of monitoring can be gradually reduced as the patient's BP stabilizes and no significant fluctuations are observed. Home BP monitoring (HBPM) offers a convenient and effective way for patients to track their BP in their natural environment. HBPM has been shown to improve BP control and reduce cardiovascular risk in hypertensive individuals. It empowers patients to take an active role in their healthcare and facilitates timely communication with their healthcare providers regarding any concerning BP changes. In some cases, particularly for patients with complex or labile hypertension, ABPM may be warranted. ABPM involves wearing a portable BP monitor that automatically records BP readings at regular intervals throughout the day and night. This provides a more comprehensive assessment of BP variability and can help identify patterns that may not be apparent with isolated clinic or home measurements. The importance of open communication and collaboration between patients and healthcare providers cannot be overstated. Patients should be encouraged to share their BP readings with their providers, who can then interpret the data in the context of the patient's overall health status and make informed decisions regarding treatment adjustments or further investigations. In some cases, adjustments to antihypertensive medications may be necessary to maintain BP control after mRNA COVID-19 vaccination. The observed BP changes, although subtle in this study, could potentially exacerbate pre-existing hypertension or unmask masked hypertension, leading to adverse cardiovascular outcomes. Therefore, healthcare providers should be prepared to modify antihypertensive therapy as needed to ensure optimal BP control. The decision to adjust medication should be based on a comprehensive assessment of the patient's BP readings, comorbidities, medication tolerance, and overall health status. A one-size-fits-all approach is not appropriate, as the optimal medication regimen will vary from patient to patient. In some cases, a temporary increase in medication dosage or the addition of a second agent may be necessary to manage BP elevations after vaccination. Once the BP stabilizes, the medication regimen can be re-evaluated and adjusted accordingly. For patients with persistent BP elevations or progression to a higher hypertension severity category, long-term modifications to the medication regimen may be warranted. This could involve switching to a different medication class, adding a third agent, or intensifying lifestyle modifications. The process of medication adjustment should involve shared decision-making between the patient and healthcare provider. The patient's preferences, concerns, and treatment goals should be taken into account when selecting the most appropriate medication regimen. Patient education plays a crucial role in the management of hypertension and the prevention of cardiovascular complications. In the context of mRNA COVID-19 vaccination, it is essential to educate hypertensive patients about the potential for BP changes and empower them to take an active role in monitoring and managing their BP. Patients should be informed about the potential for both increases and decreases in BP after vaccination. They should be educated about the signs and symptoms of elevated BP, such as headache, dizziness, and blurred vision, and encouraged to seek medical attention if they experience any concerns. The importance of regular BP monitoring, both at home and in clinical settings, should be emphasized. Patients should be instructed on proper BP measurement techniques and advised to keep a log of their readings to share with their healthcare providers. The importance of medication adherence should be reiterated, as even minor deviations from the prescribed regimen can impact BP control. Patients should be encouraged to discuss any concerns or difficulties with their medications with their healthcare providers. The role of lifestyle modifications in managing hypertension should be highlighted. Patients should be advised to adopt a healthy diet, engage in regular physical activity, maintain a healthy weight, limit alcohol intake, and avoid smoking. These lifestyle changes can complement medication therapy and contribute to better BP control. Patients should be encouraged to maintain open communication with their healthcare providers regarding any questions or concerns they may have about their BP or the impact of vaccination. This open dialogue fosters trust and collaboration, leading to better patient outcomes. Further research is needed to identify specific subgroups of hypertensive patients who may be at higher risk for significant BP fluctuations after mRNA COVID-19 vaccination. This information could help tailor preventive and management strategies to individual patient needs. Factors such as age, sex, comorbidities, medication regimens, and genetic predisposition could all influence BP responses to vaccination. Older individuals and women may be more susceptible to BP changes after vaccination due to age-related vascular changes and hormonal fluctuations. Patients with comorbidities such as diabetes, chronic kidney disease, or heart failure may have a less resilient cardiovascular system and be more prone to BP fluctuations. Certain medications, particularly those that affect the immune system or the RAS, could interact with the vaccine and influence BP responses. Genetic factors could also play a role in BP responses to vaccination. Identifying genetic markers associated with increased susceptibility to BP changes could help personalize preventive and management strategies. By identifying high-risk subgroups, healthcare providers can implement targeted interventions to mitigate the potential cardiovascular risks associated with mRNA COVID-19 vaccines. This could involve closer BP monitoring, more frequent medication adjustments, or intensified lifestyle counseling.[15-17]

The findings of this study, which suggest a potential link between mRNA COVID-19 vaccines and subtle blood pressure (BP) changes in hypertensive patients, carry significant implications for public health recommendations and vaccination strategies. The following discussion elaborates on these implications, emphasizing the importance of vaccine safety monitoring, updating vaccination guidelines, and maintaining open communication and transparency with the public. The safety of vaccines is paramount in public health, and the observed BP changes, although generally mild and self-limiting, underscore the importance of continued monitoring of vaccine safety and adverse events. The long-term cardiovascular consequences of mRNA COVID-19 vaccines, particularly in individuals with pre-existing hypertension, remain an area of active investigation. Public health agencies should maintain robust surveillance systems to track and evaluate any potential long-term effects, ensuring that the benefits of vaccination continue to outweigh the risks. The implementation of comprehensive post-marketing surveillance programs is crucial for identifying and characterizing any rare or delayed adverse events associated with mRNA COVID-19 vaccines. These programs should include active data collection from healthcare providers, patients, and vaccine registries, as well as passive reporting systems that allow individuals to report any adverse events they experience after vaccination. The data collected through these programs can be analyzed to identify any potential safety signals, including cardiovascular events, and inform further investigations and regulatory actions. The long-term cardiovascular effects of mRNA COVID-19 vaccines, particularly in vulnerable populations such as hypertensive individuals, warrant further investigation. Longitudinal studies that follow vaccinated individuals for several years and monitor their BP, cardiovascular events, and overall health status are needed to assess the potential long-term impact of these vaccines. These studies should also include a control group of unvaccinated individuals to account for the natural progression of cardiovascular disease and other potential confounding factors. The sharing of data between researchers, healthcare providers, and public health agencies is essential for advancing our understanding of vaccine safety and identifying any potential risks. Collaborative efforts can facilitate the pooling of data from various sources, enabling more robust analyses and the identification of rare or subtle adverse events that might not be apparent in smaller studies. Current vaccination guidelines do not specifically address BP monitoring or management in hypertensive individuals. The findings of this study and others suggest that such recommendations may be warranted, especially for patients with poorly controlled hypertension or other cardiovascular risk factors. Updating vaccination guidelines to include specific recommendations for hypertensive individuals can help optimize vaccine safety and minimize cardiovascular risks. A thorough pre-vaccination assessment of hypertensive patients, including a review of their BP control, medication adherence, and comorbidities, can help identify individuals at higher risk for BP fluctuations after vaccination. This assessment can inform personalized recommendations regarding BP monitoring and management. Clear guidelines on the frequency and timing of BP monitoring post-vaccination should be provided to hypertensive patients. The use of home BP monitoring should be encouraged, and patients should be instructed on proper measurement techniques and how to interpret their readings. Recommendations on medication adjustments in response to BP changes after vaccination should be included in the guidelines. Healthcare providers should be advised to consider individual patient factors and collaborate with patients to develop appropriate treatment plans. The importance of lifestyle modifications, such as diet, exercise, and stress management, in managing hypertension and minimizing cardiovascular risk should be emphasized in the vaccination guidelines. Patients should be encouraged to adopt healthy lifestyle habits and seek support from healthcare providers or community resources as needed. Open and transparent communication about the potential risks and benefits of vaccination is crucial for maintaining public trust and confidence. The findings of this study, which suggest a potential link between mRNA COVID-19 vaccines and BP changes, should be communicated clearly and honestly to the public. Healthcare providers and public health officials should proactively address concerns about BP changes after vaccination and provide evidence-based guidance to patients and the public. Healthcare providers should initiate conversations with hypertensive patients about the potential for BP changes after vaccination. This can be done during pre-vaccination consultations or through educational materials and resources. Patients should be encouraged to ask questions and express any concerns they may have. Public health officials should provide clear and concise information about the potential risks and benefits of mRNA COVID-19 vaccines, including the possibility of BP changes. This information should be based on the latest scientific evidence and presented in a way that is easily understandable to the general public. The spread of misinformation and vaccine hesitancy can undermine public health efforts. Healthcare providers and public health officials should actively address any misinformation or concerns about BP changes after vaccination, providing accurate and reassuring information based on scientific evidence. Maintaining transparency and building trust with the public is essential for successful vaccination campaigns. Public health agencies should be transparent about the ongoing monitoring of vaccine safety and any potential adverse events, including cardiovascular effects. This transparency can help foster trust and encourage vaccine acceptance.[18-20]

4. Conclusion

The present study reveals a potential association between mRNA COVID-19 vaccines and alterations in blood pressure, particularly a significant reduction in diastolic blood pressure, among hypertensive patients. The clinical implications of these changes, although seemingly minor, necessitate further investigation to ascertain their long-term effects on cardiovascular health. The study underscores the importance of vigilant blood pressure monitoring and personalized management strategies for hypertensive individuals post-vaccination.

5. References

1. Angeli F, Reboldi G, Trapasso M, Santilli G, Zappa M, Verdecchia P. Blood pressure increase following COVID-19 vaccination: a systematic overview and meta-analysis. J Cardiovasc Dev Dis. 2022; 9(5): 150.
2. Bouhanick B, Montastruc F, Tessier S. Hypertension and COVID-19 vaccines: are there any differences between the different vaccines? A safety signal. Eur J Clin Pharmacol. 2021; 77(12): 19378.
3. Ioannou GN, Locke ER, O'Hare AM. COVID-19 vaccination effectiveness against infection or death in a national U.S. health care system a target trial emulation study. Ann Intern Med. 2022; 175(3): 352-61.
4. Kurniasih KI. Analysis of antihypertension therapy in hypertension BPJS patients in Purbalingga District. J Sci Horiz. 2022; 2(4): 1283-300.
5. Kurniasari Y, Anggreny DE, Ekawati D. Determinants of side effects post-COVID-19 vaccination in the elderly in the work area of the Multiwahana Health Center Palembang City. Health Care: Health J. 2022; 11(2): 391-402.
6. Masdalena M, Muryanto I, Efendi AS. Comorbid risk factors for COVID-19 mortality at Hospital X Pekanbaru in 2021. Mulawarman Public Health J. 2021; 3(2): 105-17.
7. Meo SA, Bukhari IA, Akram J, Meo AS, Klonoff DC. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna vaccines. Eur Rev Med Pharmacol Sci. 2021; 25(3): 1663-79.
8. Nandy K, Salunke A, Pathak SK. Coronavirus disease (COVID-19): a systematic review and meta-analysis to evaluate the impact of various comorbidities on serious events. 2020.
9. Rahayu LAD, Admiyanti JC, Khalda YI. Hypertension, diabetes mellitus, and obesity as the main comorbidity factors for mortality in COVID-19 patients: a literature review. JIMKI: Indones J Med Stud. 2021; 9(1): 90-97.
10. Schwartz GL, Sheps SG. A review of the sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Curr Opin Cardiol. 1999; 14(2): 161-8.
11. Siddique S, Ahmed S. COVID-19 vaccines in Pakistan: efficacy, adverse effects and

availability. J Islamabad Med Dent Coll. 2021; 10(2): 125-30.

12. Tignanelli CJ, Ingraham NE, Sparks MA. Antihypertensive drugs and risk of COVID-19? Lancet Respir Med. 2020; 8(5): e30-e31.
13. Watanabe Y, Mendonça L, Allen ER. Native-like SARS-CoV-2 spike glycoprotein expressed by ChAdOx1 nCoV-19/AZD1222 vaccine. ACS Cent Sci. 2021; 7(4): 594-602.
14. Cevik M, Kuppalli K, Kindrachuk J, Peiris M. Virology, transmission, and pathogenesis of SARS-CoV-2. BMJ. 2020; 371.
15. Huang I, Lim MA, Pranata R. Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia - A systematic review, meta-analysis, and meta-regression. Ann Oncol. 2020; 19-22.
16. Lamb YN. BNT162b2 mRNA COVID-19 vaccine: first approval. Drugs. 2021; 81(4): 495-501.
17. Lidiana EH, Mustikasari H, Pradana KA, Permatasari A. Characteristics of adverse events following COVID-19 vaccination among Healthcare Workers Alumni of 'Aisyiyah University Surakarta. Sci J Health. 2021; 11(1): 11-17.
18. Meylan S, Livio F, Foerster M, Genoud PJ, Marguet F, Wuerzner G. Stage III hypertension in patients after mRNA-based SARS-CoV-2 vaccination Sylvain. J Hum Hypertens. 2021; 30(6): 386–91.
19. Simonini A, Lanzoni C, Cicala V. Blood pressure elevation after COVID-19 vaccination with mRNA vaccines: a case series. Vaccines. 2022; 10(1): 104.
20. Zappa M, Verdecchia P, Spanevello A. Blood pressure increase after Pfizer/BioNtech SARS-CoV-2 vaccine. Eur J Intern Med. 2021.